Detalhe da pesquisa
1.
Omalizumab for the Treatment of Multiple Food Allergies.
N Engl J Med
; 390(10): 889-899, 2024 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38407394
2.
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.
J Allergy Clin Immunol
; 149(3): 957-965.e3, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34530020
3.
Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
Dermatol Ther
; 35(4): e15303, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984792
4.
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
J Allergy Clin Immunol
; 146(3): 595-605, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32524991
5.
Reply.
J Allergy Clin Immunol
; 147(1): 413-414, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33160643
6.
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Pituitary
; 18(5): 604-12, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25537481
7.
Safety and tolerability of canakinumab, an IL-1ß inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies.
Cardiovasc Diabetol
; 13: 94, 2014 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24884602
8.
Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38389387
9.
Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment.
Int J Clin Pharmacol Ther
; 51(9): 693-703, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782585
10.
Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study.
J Asthma Allergy
; 16: 625-636, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37360967
11.
Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH).
J Allergy Clin Immunol Glob
; 1(4): 225-232, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37779534
12.
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
Br J Clin Pharmacol
; 70(1): 34-42, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20642545
13.
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
J Clin Endocrinol Metab
; 93(2): 459-64, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18042650
14.
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
J Clin Pharmacol
; 48(1): 85-95, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17986525
15.
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.
Br J Clin Pharmacol
; 65(3): 338-46, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17961192
16.
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
J Clin Endocrinol Metab
; 92(4): 1249-55, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17244786
17.
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
Clin Pharmacokinet
; 46(9): 787-802, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17713976
18.
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
Clin Pharmacokinet
; 46(7): 577-88, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17596103
19.
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
J Clin Pharmacol
; 47(5): 633-41, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17442688
20.
Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.
J Clin Pharmacol
; 47(8): 998-1004, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17660482